title: [The therapeutic efficacy of tumor-derived heat shock protein70 combining interleukin-2 on tumor-bearing mice].
abstract: OBJECTIVE
  To investigate the therapeutic efficacy of the combination of tumor-derived HSP70 and IL-2 on tumor-bearing mice.
  
  
  METHODS
  HSP70 was purified from the murine tumor cell line by liquid chromatography. And then identified by SDS-PAGE and Western blot,the purity of purified product was analyzed by capillary electrophoresis. The anti-tumor efficacies of mono-administration of HSP70 or IL-2 and their combination were observed by zoopery.
  
  
  RESULTS
  Combination of HSP70 and IL-2 was more effective than either of the two therapeutic agents alone in treating tumor-bearing mice. 10 microg HSP70 displayed obviously therapeutic effect no matter applied alone or combined with IL-2. The averaged life span of the mice treated with IL-2 was only 36.6+/-13.0 days, while 40% of the mice treated with 10 microg HSP70, tumors disappeared eventually and their survival time was more than 90 days, and the averaged life span of this group was over 59.2+/-29.6 days. HSP70 plus IL-2 could get tumors disappeared completely in 60% of mice, averaged life time of this group was over 70.8+/-26.5 days.
  
  
  CONCLUSIONS
  The Combination of HSP70 and IL-2 demonstrated apparently therapeutic effect on tumor-bearing mice. The results will be of greater value to the study on the immunotherapy of human malignant tumors.
authors.affiliation: Department of The Second General Surgery, First Clinical College, China Medical University, Shenyang 110001, China. Qingguofu@hotmail.com
authors.forename: Qing-guo
authors.initials: QG
authors.lastname: Fu
authors.forename: Fan-dong
authors.initials: FD
authors.lastname: Meng
authors.forename: Xiao-dong
authors.initials: XD
authors.lastname: Shen
authors.forename: Ren-xuan
authors.initials: RX
authors.lastname: Gou
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D003131:Combined Modality Therapy; D005260:Female; D018840:HSP70 Heat-Shock Proteins / Q000008:administration & dosage / Q000302:isolation & purification / Q000627:therapeutic use*; D007167:Immunotherapy; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*; D008114:Liver Neoplasms, Experimental / Q000737:chemistry / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008815:Mice, Inbred Strains; D009368:Neoplasm Transplantation; D015996:Survival Rate
chemical_list: D018840:HSP70 Heat-Shock Proteins; D007376:Interleukin-2